Bio-Rad Laboratories, Inc. Class A Common Stock vs Open Text Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.61 (market cap $9.43B), while Open Text Corporation trades at $23.51 (market cap $5.80B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Open Text Corporation pays a 4.67% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | OTEX | |
|---|---|---|
Market Cap | $9.43B | $5.80B |
Sector | Health | Technology |
52-Week High | $356.25 | $39.69 |
52-Week Low | $241.71 | $20.01 |
Enterprise Value | $9.18B | $10.81B |
Dividend Yield | — | 4.67% |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Open Text Corporation (OTEX) trades at $23.27, down 5.87% over the past day, with a bullish technical signal despite recent weakness. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.23 versus $1.02 expected, and maintains solid fundamentals including a 73.74% gross margin and 12.26% net income margin. Recent news highlights cloud revenue growth and a $105 million AI investment in Europe.
Outlook remains positive with a consensus price target of $29.33 implying 26% upside, supported by earnings beats and strategic AI investments. Risks include high debt levels and competitive pressures in the software sector. The stock offers value with a P/E of 9.29 and a 4.7% dividend yield.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →